Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Northwest Biotherapeutics (NWBO) Leases (2019 - 2025)

Northwest Biotherapeutics (NWBO) has 7 years of Leases data on record, last reported at $4.3 million in Q3 2025.

  • For Q3 2025, Leases fell 4.76% year-over-year to $4.3 million; the TTM value through Sep 2025 reached $4.3 million, down 4.76%, while the annual FY2024 figure was $4.2 million, 0.1% changed from the prior year.
  • Leases reached $4.3 million in Q3 2025 per NWBO's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Leases topped out at $5.1 million in Q1 2021 and bottomed at $4.0 million in Q3 2022.
  • Average Leases over 5 years is $4.4 million, with a median of $4.2 million recorded in 2023.
  • Peak YoY movement for Leases: rose 21.6% in 2021, then dropped 18.37% in 2022.
  • A 5-year view of Leases shows it stood at $4.9 million in 2021, then dropped by 14.32% to $4.2 million in 2022, then decreased by 0.14% to $4.2 million in 2023, then increased by 0.1% to $4.2 million in 2024, then grew by 2.7% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $4.3 million in Q3 2025, $4.4 million in Q2 2025, and $4.2 million in Q1 2025.